- ￥620 - 2200
- 善本生物
- 2143
- 2025年12月11日
- Western Blotting (WB), Flow Cytometry (FCM)
- 兔
- Human, Mouse, Rat
企业认证
相关产品推荐更多 >
KD-Validated Anti-ABCG2 Rabbit Monoclonal Antibody #61391
￥650
KD-Validated Anti-Histone H3 (acetyl K56) Rabbit Monoclonal Antibody #61772
￥650KD-Validated Anti-Ku70 Rabbit Monoclonal Antibody #61879
￥650
Anti-Sirtuin 1 Rabbit Monoclonal Antibody #7367
￥620KD-Validated Anti-Cyclin e2 Rabbit Monoclonal Antibody #61601
￥650
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 浓度：
Recommended Dilutions：Western Blotting (WB): 1:1,000-1:5,000 Flow Cytometry (FCM): 1:2,000
- 应用范围：
Western Blotting (WB), Flow Cytometry (FCM)
- 宿主：
兔
- 适应物种：
Human, Mouse, Rat
- 保质期：
One year
- 克隆性：
Rabbit mAb
- 保存条件：
Store at -20 °C for one year. Supplied in PBS (pH 7.4) containing 50% glycerol, and 0.02% sodium azide.
- 形态：
液体
- 亚型：
Rabbit IgG
- 免疫原：
A synthesized peptide derived from human IGF2
- 规格：
20ul/50ul/100ul
| 规格： | 20ul | 产品价格： | ￥620.0 |
|---|---|---|---|
| 规格： | 50ul | 产品价格： | ￥1200.0 |
| 规格： | 100ul | 产品价格： | ￥2200.0 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Dynamic Monitoring of Cellular Remodeling Induced by the Transforming Growth Factor-β1
Signaling and Sigma-Aldrich). Anti-β-actin (A5441) was from Sigma-Aldrich; horseradish peroxidase-conjugated anti-mouse IgG (#NA931) and anti-rabbit IgG (#NA934) were from GE Healthcare. Detection of antibody reactivity was performed using Immobilon Western
Dynamic Monitoring of Cellular Remodeling Induced by the Transforming Growth Factor-β1
Signaling and Sigma-Aldrich). Anti-β-actin (A5441) was from Sigma-Aldrich; horseradish peroxidase-conjugated anti-mouse IgG (#NA931) and anti-rabbit IgG (#NA934) were from GE Healthcare. Detection of antibody reactivity was performed using Immobilon Western
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料
